Position
Fidelity in Neurocrine Biosciences Inc
Back to the book · All holders of NBIX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $5.7M$131.74 → $168.53
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 70.5K | $10M | — | — | — | 0.0% |
| Q1 2026 | 154.9K | $20.4M | $131.74 | −$711K | $11.1M | 0.0% |
| Q2 2026 | 314K | $52.9M | $168.53 | $5.7M | $26.8M | 0.0% |